Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
about
New β-Lactamase Inhibitors in the ClinicRole of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult SubjectsNew Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development.Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects.Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.Recent developments in antibiotic agents for the treatment of complicated intra-abdominal infections.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Multidrug-resistant bacteria in hematology patients: emerging threats.β-Lactams and β-Lactamase Inhibitors: An Overview.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?Recent Advances in the Rational Design and Optimization of Antibacterial Agents.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.Novel Beta-Lactamase Inhibitors: Unlocking Their Potential in Therapy.ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.Bifunctional antimicrobial conjugates and hybrid antimicrobials.Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.Meropenem-Vaborbactam Resistance Selection, Resistance Prevention, and Molecular Mechanisms in Mutants of KPC-Producing Klebsiella pneumoniae.In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae.Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.Inhibition of Acinetobacter-Derived Cephalosporinase: Exploring the Carboxylate Recognition Site Using Novel β-Lactamase Inhibitors.Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics Vaborbactam and Meropenem Alone and in Combination Following Single and Multiple Doses in Healthy Adult Subjects.Meropenem-Vaborbactam Tested against Contemporary Gram-Negative Isolates Collected Worldwide during 2014, Including Carbapenem-Resistant, KPC-Producing, Multidrug-Resistant, and Extensively Drug-Resistant Enterobacteriaceae.Diversity and Proliferation of Metallo-β-Lactamases: a Clarion Call for Clinically Effective Metallo-β-Lactamase InhibitorsMeropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections
P2860
Q26747150-596A8E09-C4E5-46C5-A569-D705C0656A44Q33816251-C13EB710-B829-4A7C-BA94-73485269D143Q34537388-24CDD615-C665-4855-B4CE-E4E8EEC98E2BQ36153263-D1542AD8-4782-4178-91A8-EBBD4B04620DQ36290773-57FFF4A7-8179-4E2A-A03B-371CC9443948Q37203731-67784BA7-B5D2-44A6-8071-230772882FBFQ38648594-0056E0D7-8405-45C7-A310-C92EC10944DAQ38672016-2A7AE6D8-1EE4-48B1-ADB1-2B40AFE07D91Q38838498-92676C70-3CD9-4208-9D96-14D4B11936F3Q38872374-7693BD9D-1F22-47D6-950C-03D0E164AC36Q38892589-C493BA05-6EA1-4FAA-BC14-4629ADCDB57FQ38958278-83D04982-F649-44D6-89A0-496EC9EF6C0BQ39120027-C6580198-67B7-4B40-BB26-D5C3ADEBEB52Q39183212-7D73931F-D413-40FB-9D56-3E512186B27AQ40152356-FF020286-DD3A-4A3B-9B9E-AAE1F262DBB1Q40203926-F5CC6BCB-3A2B-470F-A2A6-7984246A36CAQ42638031-1ECFA6F7-1BAF-410D-9EF7-4A848D1F7BF7Q46243175-C53D4A20-06B9-440C-9E9C-AC9FE1CF241CQ46306375-A52CB126-B6D1-427D-BE21-4312DD9BD99DQ47129277-502658B2-96CF-4450-BAD5-48A28DF833B8Q47604376-87B60DE1-6660-45F0-8F5A-FF0BDF78390FQ47706889-7B240FF6-184C-4A0B-85DD-1E7D14913691Q47781210-336BB341-9BC4-4E30-BE00-97FC2BEB8FACQ50044367-6C7D6CF7-BD5E-4161-B6C8-A64A6C320CE5Q53735018-D47F6CFC-62FB-4708-AAC7-790A6DE155E7Q58641878-E169777D-DE1A-46E2-BB29-B462842035CFQ58733616-EE3B8284-9138-4B90-9BE2-8D3C18622542
P2860
Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Activity of Meropenem Combined ...... cal Isolates in New York City.
@en
type
label
Activity of Meropenem Combined ...... cal Isolates in New York City.
@en
prefLabel
Activity of Meropenem Combined ...... cal Isolates in New York City.
@en
P2093
P2860
P356
P1476
Activity of Meropenem Combined ...... cal Isolates in New York City.
@en
P2093
Amabel Lapuebla
Carl Urban
Christopher Cortes
David Landman
John Quale
Marie Abdallah
Olawole Olafisoye
P2860
P304
P356
10.1128/AAC.00843-15
P407
P577
2015-06-01T00:00:00Z